1075-35-0

应用筛选条件

关键词:'1075-35-0'

显示 1-2 共 2 条结果关于 "1075-35-0" 范围论文

Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.

Hyo-Soo Kim et al.

Lancet (London, England), 396(10257), 1079-1089 (2020-09-04)

A potent P2Y12 inhibitor-based dual antiplatelet therapy is recommended for up to 1 year in patients with acute coronary syndrome receiving percutaneous coronary intervention (PCI). The greatest benefit of the potent agent is during the early phase, whereas the risk

Effect of selected antioxidants in beta-cyfluthrin-induced oxidative stress in human erythrocytes in vitro.

Izabela Sadowska-Woda et al.

Toxicology in vitro : an international journal published in association with BIBRA, 24(3), 879-884 (2009-12-08)

beta-Cyfluthrin is one of the most widely used type II pyrethroid in agriculture. The aim of this study was to examine (1) the possibility of beta-cyfluthrin to induce oxidative stress in human erythrocytes in vitro and its effect on catalase

1/1